NicOx
Tracked across 4 events · 26 articles · First seen Jun 03, 2026 · Last active Aug 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: NicOx is holding an Ordinary and Extraordinary General Meeting where an ad hoc representative has been appointed to ensure quorum due to difficulties in shareholder participation.
Jun 03, 2026 · 6 articles
Business
Impact: NicOx is the issuer of the warrants that are expiring, and the event directly impacts its share structure and investor base.
Jun 08, 2026 · 7 articles
Business
Impact: NicOx, an international ophthalmology company, announced positive regulatory feedback for its drug NCX 470 in China, which is expected to lead to a New Drug Application submission. This development is positive for NicOx as it could lead to future royalties and milestone payments.
Jun 18, 2026 · 7 articles
Regulatory
NicOx announced that its exclusive licensee in China, Paragon Therapeutics, has submitted a New Drug Application (NDA) to the Chinese China — National Medical Products Administration (NMPA) for NCX 470, a novel nitric oxide-donating bimatoprost…
Impact: NicOx is the developer of NCX 470 and stands to benefit from potential royalties and milestone payments. The NDA submission in China is a key step toward commercialization, positively impacting its pipeline value.
Aug 10, 2026 · 6 articles
90
NicOx announced submissionNCX 470 NDA submitted in China
80
Paragon Therapeutics paid license fees NicOxNCX 470 NDA submitted in China
70
NicOx received royalties Paragon TherapeuticsNCX 470 NDA submitted in China
60
Paragon Therapeutics contributed trial costs NicOxNCX 470 NDA submitted in China
ERGEN INTELLIGENCE
Track NicOx live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard